Not only does this position SNHG1 or PTEN as a promising new biomarker for the early detection, diagnosis, and prognostic assessment of BC, but it also suggests that targeting SNHG1 or PTEN can be a viable strategy for the prevention and treatment of BCs. Here, SNHG1 is linked to breast cancer.